Reshape Lifesciences INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
Vyome Holdings, Inc. reported a significant net loss for fiscal year 2025, while advancing its lead drug candidate VT-1953 for malignant fungating wounds and outlining plans for future clinical trials and capital raises.
ReShape Lifesciences Inc. details its 2024 financial performance and strategic initiatives, including a pending merger with Vyome Therapeutics and an asset sale to Ninjour Health International, while navigating challenges in the weight-loss market.
ReShape Lifesciences Inc. focuses on strategic growth pillars, including cost reduction and product portfolio expansion, while facing revenue declines due to market competition.